Patients

As a company addressing some of the world’s most difficult-to-treat conditions, we see patients as our inspiration and equal partners in our mission to harness the building blocks of life to work in harmony with the body’s immune system.

Our current work with patients is focused on clinical studies of IMNN-001, which targets the micro-environment of ovarian cancer by harnessing the body’s immune system to produce safe and durable levels of a powerful anti-cancer immune agent, IL-12, at the tumor site.

Clinical Studies

IMNN-001 (GEN-1) in ovarian cancer

The 201-24-301 “OVATION 3” study is a randomized phase III study evaluating the safety and efficacy of Intraperitoneal IMNN-001 (formerly known as GEN-1, IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) administered in combination with standard neoadjuvant and adjuvant chemotherapy in newly diagnosed patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. The primary objective is to evaluate if combining IMNN-001 in combination with standard of care chemotherapy followed by standard of care maintenance therapy can improve overall survival in this patient population. This study is now enrolling at select centers throughout the United States of America with additional centers opening up soon. For more information please visit, OVATION 3 Study at clinicaltrials.gov

The 201-21-202 “MRD” study is a Phase II Study evaluating the effect of IMNN-001 (formerly known as GEN-1, IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) on Second Look Laparoscopy (SLL).  When administered in combination with Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in subjects newly diagnosed with advanced ovarian, fallopian tube or primary peritoneal cancer.  The primary endpoint of the study is to determine if the addition of IMNN-001 can reduce the rate of minimal residual disease (MRD) at SLL from an expected 70% in the control group (chemotherapy + BEV) to 35% in the experimental group (chemotherapy + BEV + IMNN-001).  This is a randomized, open lablel, multicenter trial in which eligible subjects will be assigned 1:1 to the treatment and control arms.  The study will also evaluate progression free survival and overall survival between the two arms.

View the MRD Study at clinicaltrials.gov

OVATION 2 is a Phase I/II study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. The primary objective of the study is to evaluate safety and compare progression free survival between neoadjuvant chemotherapy (NACT) plus IMNN-001 versus standard NACT. This is a randomized, open label, multicenter trial in which eligible subjects will be assigned 1:1 to the treatment and control arms. The phase II portion has completed and readout results.  See more.

View the Ovation 2 Study at clinicaltrials.gov

OVATION I was a Phase I Study of the Safety & Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Standard Neoadjuvant Chemotherapy in Patients Newly Diagnosed with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. The primary endpoint was determination of a recommended Phase II dose of IMNN-001 in combination with standard neoadjuvant therapy. It had a standard 3+3 design with approximate 30% dose increments between successive cohorts of patients. The results of OVATION 1 have been published in the journal Clinical Cancer Research.

View the Ovation I Study at clinicaltrials.gov

For Patients

about ovarian cancer

Chapter 1 - Ovarian Cancer Background

Chapter 2 - IMNN-001 Background

Chapter 3 - Ovation 3 Study Information

OVATION 3 Study: A Randomized Phase III Study Evaluating the effect of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) on overall survival.

Administered in Combination with Neoadjuvant and Adjuvant Chemotherapy  in Patients Newly Diagnosed with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.

MRD Study: A Phase II Study Evaluating the effect of IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) on Second Look Laparoscopy (SLL).

Administered in Combination with Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in Subjects Newly Diagnosed with advanced ovarian, fallopian tube or primary peritoneal cancer.

Chapter 1 - Ovarian Cancer Background

Chapter 2 - IMNN-001 Background

Chapter 3 - MRD Study Information

Resources

Ovarian Cancer Advocacy Programs

Tell Every Amazing Lady About Ovarian Cancer

Louisa M. McGregor Ovarian Cancer offers women’s health and wellness services, including public awareness and education of the signs, symptoms, and risk factors of ovarian cancer, proved support to those impacted by the disease and raises funds for research in order to find a screening test and a cure.

www.TellEveryAmazingLady.org

Tell Every Amazing Lady logo

Expanded Patient Access Policy

Patients are our partners, our inspiration, and are behind our commitment to IMUNON’s mission, goals, and development of IMNN-001.

IMUNON believes that participation in one of our clinical trials is the most appropriate way to access our investigational therapies. For more information, visit ClinicalTrials.gov.

At this time, IMUNON is not offering IMNN-001 or any other investigational products under the Expanded Access program.

 

Jeffrey W. Church

interim Chief Financial Officer

Jeffrey W. Church joined Imunon in July 2010 as Vice President and Chief Financial Officer. Mr. Church was appointed Senior Vice President and Chief Financial Officer of Imunon in July 2013. The appointment marked Mr. Church’s resumption of the role of Chief Financial Officer, a position he held prior to his promotion to Senior Vice President in July 2011, while also granting him responsibility for corporate investor relations. In 2018, Mr. Church was appointed Executive Vice President and Chief Financial Officer and Corporate Secretary and where he served in this capacity until his retirement in June 2024. In January 2026, Mr. Church was appointed interim Chief Financial Officer. He has over 30 years of experience in corporate finance, mergers and acquisitions, investor relations, and SEC reporting. Prior to joining Imunon, Mr. Church held senior financial executive positions with several private and public clinical-stage life science companies, including Alba Therapeutics Corporation, Novavax, Inc., GenVec, Inc., and Meridian Medical Technologies, Inc. Mr. Church started his career in 1979 with the public accounting firm Price Waterhouse. Mr. Church holds a BS degree from the University of Maryland and received his Maryland Certified Public Accountant accreditation in 1979.

Khursheed Anwer, PhD, MBA

Executive Vice President and Chief Science Officer

Khursheed Anwer, PhD, MBA, assumed the title of Executive Vice President and Chief Science Officer, upon Imunon’s June 2014 acquisition of EGEN, Inc., where he was President and Chief Science Officer, a position he held since 2009. He joined EGEN, Inc. in July, 2002, as Vice President of Research and Development, and directed the company’s clinical and research and development functions throughout his tenure at EGEN, Inc. Dr. Anwer has a PhD in Physiology/Pharmacology from Ohio University and received postdoctoral training from the University of Texas Health Science Center at Houston. Before joining EGEN, Inc., Dr. Anwer was Director of Pre-Clinical Development at Valentis, Inc. From 1993 to 1999, he served in several positions at GeneMedicine, Inc., where he led several research projects in the area of nonviral gene therapy. He has authored more than 40 publications in the area of nonviral gene therapy, resulting from his active career in research and development. Dr. Anwer has served as an adjunct faculty member in the Biology Department at the University of Alabama in Huntsville and a board member of the University of Alabama Business School, STEP.

Sebastien Hazard, M.D.

Executive vice president & chief Medical officer

Dr. Sebastien Hazard, M.D. was appointed Executive Vice President and Chief Medical Officer of Imunon in December 2023.  Prior to joining Imunon, Dr. Hazard served as Senior Vice President, Head of Clinical Development at Bicycle Therapeutics plc from April 2021 through September 2023.  Prior to joining Bicycle Therapeutics, Dr. Hazard served as Clinical Development Lead at GSK from June 2019 to April 2021.  He also served as Senior Medical Director of Clinical Development from July 2018 to May 2019, and Senior Medical Director of Global Medical Affairs from August 2016 to July 2018 at TESARO, Inc.  Dr. Hazard held various positions within Genentech including Medical Director in Lung Cancer of US Medical Affairs from November 2012 to July 2016.  Earlier in his career Dr. Hazard served as an advisor to the head of the French Drug Agency and to the French Health Minister’s cabinet.  Dr. Hazard holds a Doctorate in Medicine, Internal Medicine and Public Health from Paris VI Pitie Salpetriere an Executive MBA from INSEAD and Master’s degree in epidemiology and statistics applied to clinical research from Paris VI University.